Dr. Chris Martin has been appointed chief executive officer, ADC Therapeutics Sarl. Dr. Martin was co-founder of Spirogen Ltd. and its chief executive officer leading up to the sale of Spirogen to MedImmune, in 2013. Dr. Martin became both a member of Medimmune’s management leadership team and AstraZeneca’s senior leaders group. Dr. Martin continues to advise Medimmune as a consultant.
 
Dr. Martin played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding. He is a recognized leader in the Antibody Drug Conjugates space, and his leadership of Spirogen led to its Best Scientific Innovation Award in 2014.
 
Dr. Martin replaces Michael Forer who will serve as vice chairman of ADC Therapeutics, and will continue to work with the company as executive vice president focused on its public markets capital strategy, business and finance activities.
 
Dr. Peter B. Corr, chairman of the board of ADCT, said, “Chris played an important role together with Michael Forer in the founding of ADC Therapeutics, and its business plan to develop proprietary PBD-based ADCs under license from Spirogen. He has contributed significantly to the business both as a board member and shareholder, and we are delighted that he has now joined the Company as CEO as we move forward with 7 PBD-based ADCs into clinical development over the next two years. We believe that PBD-based ADCs are the next-generation of cancer drugs with the potential to make a large impact on cancer patients worldwide.”